Phosphodiesterase 10A enzyme (PDE10A) is an important striatal target that has been shown to be affected in patients with neurodegenerative disorders, particularly Huntington´s disease (HD). PDE10A is expressed on striatal neurones in basal ganglia where other known molecular targets are enriched such as dopamine D 2/3 receptors (D 2/3 R). The aim of this study was to examine the availability of PDE10A enzyme in relation with age and gender and to compare those changes with those related to D 2/3 R and volumes in different regions of the basal ganglia. As a secondary objective we examined the relative distribution of D 2/3 R and PDE10A enzyme in the striatum and globus pallidus. Forty control subjects (20F/20M; age: 44 ± 11y, age range 27-69) from an ongoing positron emission tomography (PET) study in HD gene expansion carriers were included. Subjects were examined with PET using the high-resolution research tomograph (HRRT) and with 3T magnetic resonance imaging (MRI). The PDE10A radioligand 18 F-MNI-659 and D 2/3 R radioligand 11 C-raclopride were used. The outcome measure was the binding potential (BP ND ) estimated with the two-tissue compartment model ( 18 F-MNI-659) and the simplified reference tissue model ( 11 C-raclopride) using the cerebellum as reference region.
Introduction
The basal ganglia are a group of subcortical nuclei that form connected neuronal macrocircuits involved primarily in motor control but also in higher cognitive, behavioural and affective functions in the human brain. The striatum, the major input structure of the basal ganglia, is mainly composed by striatal medium spiny neurons. These neurons initiate the majority of the projections directed to the basal ganglia motor related output nuclei (Substantia Nigra pars reticulata, Globus Pallidus pars interna and externa) by means of functionally distinct and interactive mono-or polysynaptic pathways (direct, hyperdirect and indirect-pathways) (Utter and Basso, 2008) .
These integrated circuits are mantained by GABAergic and glutamatergic chemical synapses although the signaling is strongly modu-lated by dopamine. Dysfunctional activities within the circuits form the basis of several clinical syndromes, such as Parkinson's Disease (PD) and Huntington's disease (HD) (Gittis and Kreitzer, 2012; Joel and Weiner, 2000; Kravitz et al., 2010; Gerfen and Surmeier, 2011) . Well established dopaminergic targets in the striatum are the pre/post synaptic D 2/3 receptors (D 2/3 R) which are coupled with G proteins and are involved directly in the modulation of synaptic transmission mediated by dopamine.
Positron emission tomography (PET) imaging has been widely applied for the investigation of D 2/3 receptors in various physiologic conditions and in disorders of the central nervous system (CNS) (Cummings et al., 2011; Ginovart et al., 1997; Steeves et al., 2009; Vollenweider et al., 2000) . Among other striatal PET imaging targets, the intracellular Phosphodiesterase 10 A (PDE10A) enzyme has recently gained attention for a key role in the regulation of striatal signaling. PDE10A is highly expressed in medium spiny neurons of the striatum and globus pallidus, at the confluence of the corticostriatal glutamatergic and the midbrain dopaminergic pathways, where it regulates the hydrolysis of both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The resulting signaling cascade is involved in signal processing in the corticostriatothalamic circuit (Threlfell et al., 2009; Giampà et al., 2010) .
Recently, the in vivo evaluation of PDE10A density has been proposed to serve as a suitable biomarker for studying molecular changes in the GABAergic medium spiny neurons in neurological disorders. Recent PET imaging studies investigating the availability of PDE10A in HD gene expansion carriers and in PD patients Russell et al., 2016; Niccolini et al., 2015a) suggested a specific alteration of this protein along with the neurodegenerative process. Moreover, a de novo mutation in PDE10A gene have been recently identified in individuals with childhood onset chorea and bilateral striatal lesions (Mencacci et al., 2016) . All together, these findings suggest that striatal PDE10A is implicated in the pathophysiology of different neuropsychiatric disorders affecting the basal ganglia (movement disorders such Huntington's Disease or Parkinson's disease and schizophrenia).
Physiological age-related changes of molecular targets and volumes should be considered together when examining neurodegenerative disorders affecting the basal ganglia both at structural and molecular levels. Previous PET studies have examined the effect of age on D 2/3 receptors (Rinne et al., 1993; Antonini and Leenders, 1993; Kim et al., 2011) . To our knowledge imaging studies examining age-related changes of PDE10A enzyme together with other molecular and structural striatal targets (e.g. D 2/3 receptors and volumes) in the same healthy subjects are not available.
Moreover, in our view, is important when considering age-related effects on basal ganglia molecular targets such as the PDE10A enzyme and the D 2/3 receptors is important to consider that partial volume effects (PVEs) might affect the quantitative accuracy due to the limited resolution of PET and due to age-related volumetric changes (Greve et al., 2016) . A possible approach to address these issues would be to use PET systems with high spatial resolution combined with the application of methods for partial volume effect correction (PVEc).
18 F-MNI-659 is one of the available PET markers for PDE10A that has already been formally validated and has been successfully used in clinical studies in control subjects and HD gene expansion carriers Russell et al., 2016) . 11 Craclopride is a well-established radioligand for in vivo imaging of D 2/3 receptors with PET. Moreover, in view of the methodological considerations described above, we considered that PET imaging with the high-resolution research tomograph (HRRT) and with 3T high resolution MRI, in combination with PVEc, would be a suitable approach to examine molecular and volumetric changes in the striatum and globus pallidus in the normal brain. The objectives of this PET study with 18 F-MNI-659 and 11 Craclopride were to examine, in the striatum and globus pallidus of healthy volunteers: 1) the changes of PDE10A availability in relation to aging compared to D 2/3 receptors and to age-related volumetric changes measured with MRI. 2) the differences in regional distribution of PDE10A availability compared to D 2/3 receptors.
Materials and methods

Study protocol
The participants of this study had been included as age matched controls for HD gene expansion carriers in a cross sectional study that has been conducted at the Karolinska Institutet PET Center. After the inclusion in the study, the subjects were scheduled for an MRI scan and two PET measurements ( 11 C-raclopride and 18 F-MNI-659). The MRI scans were performed on average 17 ± 18 days prior to the PET examinations. Thirty-nine of these subjects performed both PET measurements during the same day ( 11 C-raclopride in the morning and 18 F-MNI-659 in the afternoon), with an interval of 2-to-4 h between PET measurements. For technical reasons, the PET measurements for one subject were performed on two separate days, at 13 days apart.
Participants
Twenty female and twenty male healthy control subjects (age: 44 ± 11y, age range 27-69) were enrolled in the study (Table 1) .
The study was approved by the Ethics Committee of the Stockholm Region, by the Radiation Safety Committee of the Karolinska University Hospital, Solna, Stockholm, Sweden. The study was registered in the EU Clinical Trials Register (EudraCT nr. 2012-003808-13) and approved by the Swedish Medicinal Product Agency. The study was performed in accordance with Good Clinical Practice guidelines. A written consent was obtained from each subject following detailed explanation of the study procedures. All subjects were screened at Karolinska Trial Alliance with a complete medical evaluation (psychiatric history, physical examination, blood chemistry, and electrocardiogram and MR imaging). Participants were considered healthy according to medical history (detailed history of possible psychiatric and neurological conditions), physical examination and neurological examination, ECG, vital signs, laboratory assessment and MRI. Subjects with any disease, condition or concomitant medications that potentially could interfere with brain functions were excluded.
Diseases and conditions and consequent medications that could potentially interfere with the knowledge of a possible interaction with the two molecular targets were evaluated for every subject. Subjects abstained from any drugs with the potential to interfere with 18 F-MNI- C-raclopride (e.g. antiparkinsonian, antipsychotics, antiemetics) or with a known pharmalogical effect on D 2/3 receptors binding (agonist and antagonist) or on dopamine transporter (e.g. tetrabenazine, reserpine, bupropion)). Subjects also abstained from any substance/medication with non-selective (e.g. caffeine, theobromine, theophylline) inhibitory effect on PDE10 for at least 48 h prior to PET measurements. Alcohol, melatonin, and nicotine-containing products were also restricted. Urine drug and breath alcohol tests were conducted before every examination. Heavy smokers not able to abstain from nicotine overnight were also excluded. The acquisitions were performed from February 2013 to May 2016.
Magnetic resonance imaging (MRI)
MRI examinations of all subjects were performed on a GE MR750 3 T system (IR-SPGR; 12 channels coil, 176 slices of 1 mm thickness, FoV=256 mm, matrix 256×256, Resolution 1×1×1 mm. TI=450 ms, TE=3.18, TR =8.16). T1-weighted MRI images were acquired for volumetric analysis, as well as for definition of regions of interest. A T2-weighted fluid attenuated inversion recovery (FLAIR) sequence was included to rule out pathology or vascular changes.
MRI image processing
The definition of regions of interest and volumetric measurements were performed with the Freesurfer image analysis package (http:// surfer.nmr.mgh.harvard.edu/). The technical details of these procedures are described in prior publications (Dale et al., 1999; Fischl et al., 2002) . Briefly, this processing includes motion correction and averaging (Reuter et al. 2010 ) of multiple volumetric T1 weighted images, removal of non-brain tissue using a hybrid watershed/surface deformation procedure (Segonne et al., 2004) , automated Talairach transformation, segmentation of the subcortical white matter and deep gray matter volumetric structures (Fischl et al., 2002; Fischl et al., 2004a) intensity normalization (Sled et al., 1998) , tessellation of the gray matter white matter boundary, automated topology correction (Fischl et al., 2001; Segonne et al., 2007) . A manual quality check of the output of the FreeSurfer analysis, for each individual MRI, was performed with the freeview software. Volumetric outcome measures were extracted for the caudatus, putamen, globus pallidus and for the intracranial volume (ICV).
Positron Emission Tomography (PET)
Radiochemistry of 11 C-raclopride and 18 F-MNI-659. 11 C-raclopride was prepared from the corresponding desmethyl precursors using 11 Cmethyl triflate following a method already described (Langer et al., 1999) . The specific radioactivity of 11 C-raclopride at time of injection was 230 ± 97 GBq/μmol. The injected radioactivity and injected mass for 11 C-raclopride were 303 ± 51 MBq and 0.7 ± 0.9 μg, respectively.
18 F-MNI-659 was prepared following a method partially already described and further implemented at the Karolinska radiochemistry laboratory (see Supplementary Materials).
The specific radioactivity of 18 F-MNI-659 at time of injection was 79 ± 32 GBq/μmol. The injected radioactivity and injected mass for 18 F-MNI-659 were 197 ± 33 MBq and 1.5 ± 0.6 μg, respectively.
PET imaging procedures. The PET measurements were performed using the High Resolution Research Tomograph (HRRT) (Siemens Molecular Imaging) (Varrone et al., 2009 ). To prevent head motion during the PET measurement, an individually molded thermoplastic helmet was made for each subject (Bergström et al., 1981 F-MNI-659 using three-dimensional ordinary Poisson ordered subset expectation maximization (OP-3D-OSEM) including the modeling of the system's point spread function (PSF) (Varrone et al., 2009 ).
An arterial line was placed prior to each PET measurement with 18 F-MNI-659 for the measurement of the arterial input function. A catheter was placed in a distal artery (radial or brachial artery) by an anesthesiologist under local anesthesia. After the injection of 18 F-MNI-659, arterial blood was collected for 10 min using an automated blood sampling system (ABSS, Allogg AB) at a rate of 5 mL/min. Arterial blood samples were collected at 1, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 70 and 90 min post-injection for measurement of blood and plasma radioactivity and metabolite analysis. Manual blood samples were separated into blood cells and plasma by centrifugation. The supernatants was firstly deproteinized and then analyzed with high-performance liquid chromatography (HPLC) to obtain the percentage of parent compound and radioactive metabolites. Both plasma and blood radioactivity of the unchanged 18 F-MNI-659 was measured in a well counter cross-calibrated with the PET system. In addition, the fraction of plasma radioactivity unbound to protein (plasma free fraction, f P ) was determined. Plasma protein binding for 18 F-MNI-659. The free fraction, f p , of 18 F-MNI-659 in plasma was estimated using an ultrafiltration method. Plasma (500 µL) or phosphate buffered saline solution (500 µL) as a control were mixed with 18 F-MNI-659 (50 µL,~1 MBq) and incubated at room temperature for 10 min. After the incubation, 200 µL portions of the incubation mixtures were pipetted into ultrafiltration tubes (Centrifree YM-30, Millipore) and centrifuged at 1,500g for 15 min. Equal aliquots (20 µL) of the ultrafiltrate (C free ) and of the plasma (C total ) were counted for their radioactivity using a gamma counter (2480 WIZARD2-D3, PerkinElmer). Each determination was performed in triplicate. The free fraction was then calculated as f p = C free / C total , and the results were corrected for the membrane binding measured with the control samples.
Radiometabolite analysis for
PET image processing. The obtained dynamic images were preprocessed with a post-reconstruction frame-to-frame correction realignment algorithm as previously described (Schain et al., 2012) . For larger movements ( > 2 mm), each frame was reconstructed separately using the realigned transmission data, after which the image was realigned to the initial position of the transmission data.
MRI was coregistered to the average PET images using the standard procedures in SPM5 (Wellcome Department of Cognitive Neurology, University College London). Average PET images were generated by averaging over frames 20-33 for 11 C-raclopride and 1-20 for 18 F-MNI-659 using Vinci 2.54 (Max-Planck Institute for Neurological Research, Cologne). Regions of interest (ROIs) of the striatum (caudate and putamen), globus pallidus and the cerebellar grey matter were obtained from the Freesurfer segmentation and parcellation of the MRI, and coregistered to PET space for derivation of regional time-activity curves (Schain, 2014) . The cerebellar grey matter was used as reference region since it has a negligible amount of D 2/3 Receptors and PDE10A enzyme (Coskran et al., 2006 (Rousset et al., 1998) was applied to correct all PET data for partial volume effect (PVE). The implementation used in this work included the estimation of the effective resolutions and point spread function of the HRRT system together with the anatomical details of ROIs boundaries provided by FreeSurfer in order to estimate a precise geometric transfer matrix.
Arterial plasma input for 18 F-MNI-659. The generation of the input function, the plasma radioactivity of unchanged radioligand over time, was performed with a standardized procedure. The time-activity curve for whole blood was generated by concatenating the ABSS curve and the manual blood samples. Plasma and blood radioactivity concentrations from manual blood samples were used to obtain the plasma/blood ratio curve in the time interval of the automatic sampling. The unchanged parent fraction was corrected for plasma recovery. The plasma free fraction, f P, of 18 F-MNI-659, was found to be on average less than 4%. The final arterial input function was generated by multiplying the plasma time-activity curve with the parent fraction.
18 F-MNI-659 and 11 C-raclopride kinetic modelling. Regional nondisplaceble binding potential values (BP ND ) were selected as outcome measure for both the radioligands.
BP ND is defined as the fraction between the specifically bound radioligand and the nondisplaceable radioligand in tissue at equilibrium (Innis et al., 2007) . The nondisplaceable uptake represents the sum of the nonspecific and free radioligand in the tissue.
BP ND for 18 F-MNI-659 was derived indirectly as V T /V ND −1, where V T represents the total distribution volume in the target regions (striatum and globus pallidus) and V ND represents distribution volume in the non-displaceable compartment. The cerebellar cortex is a region with a negligible density of PDE10A enzyme thereby a suitable reference region for the estimation of free and nonspecifically bound radioligand Lakics et al., 2010) (Svedberg et al., unpublished data) . Therefore, V ND was estimated as VT in cerebellar cortex.
For 18 F-MNI-659, V T was estimated using a 2-tissue compartment model (2TCM). In a preliminary kinetic analysis, other models (1TCM, SRTM, Logan Invasive) were discarded because of a number of fitting failures or poor model fits. 2TCM was the method that consistently generated a better fitting for all the ROIs except for the cerebellum, in all subjects. In a preliminary evaluation, the fitting of the cerebellar TACs were improved by including the blood volume fraction (vB) together with the rate constants in the 2TCM. The quality of fitting was investigated with fitting measures (Goodness of fit and F-Test) that demonstrated a significant improvement compared with the fitting estimates generated with vB from the whole brain TAC (standard procedure). Therefore for the cerebellum this procedure was selected as the gold standard model for the estimation of V T in cerebellum (i.e., V ND ). A possible explanation for this observation is that PDE10A enzyme is present in vascular tissues (Tian et al., 2011) and in a region with low signal as the cerebellum, the relative contribution of the radioactivity in the blood vessels to the PET signal might be larger than in other regions.
BP ND for 11 C-raclopride was estimated using the simplified reference tissue model (SRTM) with cerebellum as a reference region.
The outcome measures presented in this study were obtained from regional time-activity curves corrected for PVE. The decision of using PVE corrected data was based upon the knowledge that subcortical grey matters structures, in healthy subjects, are affected by age-related volumetric decline (Raz et al., 2003) and by the possibility to use the same method in clinical application such as with neurodegenerative diseases in which atrophic related changes are relevant and non linear (e.g. Huntington disease).
Thus the correction represented a possible solution to reduce the underestimation of the outcome measures due to the PVE. Results obtained using the un-corrected data are presented in the supplementary material.
Statistical analysis. Correlations between age and D 2/3 R, age and PDE10A, age and volumetric measurements were assessed separately within each region of interest with a multiple linear regression analysis. In the first model, the subject's age was used as the predictor variable 18 F-MNI-659 BP ND and 11 C-raclopride BP ND and MRI outcome measures were used as dependent variables. MRI outcome measures were normalized for the ICV.
In the second model, the subjects´s age and gender were used as predictors and the PET and MRI outcome measures were used as dependent variables and covariates as in the first model. The second model was used to confirm that correlations with age were present also when adjusting for gender. The p values of the regression coefficients were corrected for multiple comparisons with Bonferroni method, considering the number of outcome measures that were set as dependent variables. The significance level was then set to p < 0.008 (0.05/6).
Estimates of the predicted loss in 42 years (age range 27-69) for the 3 targets were obtained from the values of the slopes and the intercepts of regression analyses. The statistical analysis was conducted with SPSS v23 (IBM).
As a part of a supplementary analysis we evaluated the correlations between age and PDE10A, age and D 2/3 R, age and volumetric measurements in two different age ranges (26-44) and (46-69) with a Bivariate Pearson correlation analysis. Correlations plots, pearson r values and significance are presented as figure in the supplementary material ( supplementary figures 1 and 2) . The p values of the regression coefficients were corrected for multiple comparisons with the Bonferroni method. The significance level was then set to p < 0.008 (0.05/6).
Regional differences between the two targets were assessed with unpaired, two-tailed t-test. Bivariate Pearson correlation analysis was used to evaluate the relationship between the availability of PDE10A ( 18 F-MNI-659 BP ND ) and the availability of D 2/3 R ( 11 C-raclopride BP ND ) and in the striatum and globus pallidus. The p values of the regression coefficients were corrected for multiple comparisons with the Bonferroni method. The significance level was set to p < 0.025 (0.05/2).
Results
Regression analyses
In the first linear regression analysis, a statistically significant effect of age on PDE10A availability was observed in the striatum. The effect of age on striatal D 2/3 receptors availability did not reach statistical significance after Bonferroni's correction (Table 2) . No statistical significant effect of age on either PDE10A or D 2/3 receptor availability was observed in the globus pallidus. A statistically significant negative association was observed between age and volume of the striatum, whereas no statistically significant effect of age on the volume of globus pallidus was found.
In the second regression model that included also gender as covariate, after Bonferroni correction, the significant effect of age for PDE10A availability in the striatum was confirmed (Table 3) . When examining the individual contribution of the covariates, gender was found to be positively associated with PDE10A availability, with higher BP ND in female subjects in the striatum, although the p value was not significant after Bonferroni's correction (Table 3) .
The effect of age on D 2/3 availability in the striatum did not reach statistical significance when adjusting for gender. On the other hand, after adjustment for age, a statistically significant effect of gender on D 2/3 availability was observed in the striatum, with higher BP ND values in female subjects (Table 3) . For the volumetric measurements, as in the first model, the effect of age was detected with statistical significance only for the striatum, also when adjusted for gender. The gender did not show any effect on the volumetric measurements.
Age-related changes of PDE10A enzyme, D 2/3 receptors and MRI volumes
In the striatum the age-related decline per decade of PDE10A, D 2/3 R availability, availability and volumes were 7.8%, 4.3%, and 3%, respectively. In the globus pallidus, the age-related changes per decade of PDE10A availability, D 2/3 R availability and volumes were −3.8%, +3.2% and −0.7%, respectively.
Plots figure 1 and 2 ).
Regional distribution of the two molecular targets
A different regional distribution of the binding of the two radioligands in the striatum and in the globus pallidus was observed ( Fig. 2A-B) . BP ND values of 11 C-raclopride in the striatum (4.6 ± 0.5)
were significantly higher than BP ND values in the globus pallidus (1.1 ± 0.2) (p < 0.05). BP ND values of 18 F-MNI-659 in the striatum (6.9 ± 1.9)
were in the same range as those in the globus pallidus (8.0 ± 2.9) (Fig. 2B ).
In the in the striatum statistically significant correlation between 18 F-MNI-659 and 11 C-raclopride BP ND values were observed (Pearson correlation coefficient, r=0.53, p < 0.01) whereas a non significant correlation was observed between the two targets BP ND values in the globus pallidus (Pearson correlation coefficient, r=−0.11, p=0.49) (Fig. 2B) . The volumes of the striatum and globus pallidus measured from the segmentation of the MRI were 17527 ± 1907 mm 3 and 3145 ± 332 mm 3 , respectively.
Discussion
This PET study was performed in order to examine in vivo the effects of age on PDE10A enzyme availability; D 2/3 receptors were examined together with the corresponding age-related volume changes of the striatum and globus pallidus. The methodological approach used in this study provided a comprehensive structural and molecular evaluation of the striatal and globus pallidus complex in the basal ganglia. Striatal PDE10A availability showed a significant age-related decline that was larger compared to the age-related D 2/3 receptor and volume loss (Fig. 1) . The PDE10A enzyme showed a different distribution compared with the D 2/3 receptors, with relatively higher availability in the globus pallidus (Fig. 3) .
Effect of age on PDE10A enzyme
Our findings demonstrated that the availability of PDE10A enzyme in the striatum was significantly affected by age with an estimated loss of 8% per decade. Our results confirmed the findings recently reported by Russell (Russell et al., 2016) who described the same rate of decline per decade of PDE10A in 11 healthy subjects using the same radioligand.
Our findings obtained with PVEc confirm and reinforce the hypothesis that the reduction of apparent PDE10A availabilities reflects Table 3 Results of the multiple regression analysis between PDE10A, Dopamine D 2/3 Receptors and volumes with age and gender in the Striatum and Globus Pallidus (Model II). Displayed R and age ß values and significance levels (p) referred are shown. In bold results that survived after the correction for multiple comparison. *= MRI volumes were normalized for the Intracranial Volume (ICV). NeuroImage 152 (2017) 330-339 a genuine loss of binding targets in the aging striatal tissues and is not a reflection of an underestimation due to PVE. Studies using subjects with wider age range, including younger and elderly people are required to confirm and eventually extend the observed relationship. Noteworthy PDE10 A age-related changes explored separately in two different age subgroups of young (25-44 years old) and older adults (46-69 years old) (Supplementary figure 1 and 2) were not statistically significant. The results of this additional analysis should be considered with caution, because they were obtained in a small sample, with obvious impact on the statistical power of the analysis, and should be confirmed in a larger cohort of young or older subjects.
Model II
The molecular mechanisms and the consequences of these changes in healthy and functioning brain remain elusive and beyond the scope of the present study. However, the PDE10A enzyme displays an important decline during adulthood and is affected quite early during prodromal phases of HD (Niccolini et al., 2015b) . Our impression is that PDE10A is an enzyme relatively vulnerable to effects of physiological and neurodegenerative processes. The age-related declines observed in this study suggest the need of careful age-matching in PET studies in HD gene expansion carriers and other neurodegenerative disorders.
Effect of age on D 2/3 receptors
In this study, a negative relationship between D 2/3 receptors availability and age was found only as trend (p= 0.02) and was not tently demonstrated a significant decline in striatal D 2/3 receptor density with age, ranging from 4 to 9% per decade (Rinne et al., 1993; Antonini and Leenders, 1993; Kim et al., 2011) , and a significant reduction of pre-and postsynaptic biomarkers of brain dopamine activity during normal ageing (Reeves et al., 2002) . More recently, two different studies performed with the HRRT system and the agonist tracer 11 C(+) PHNO showed an age related decline of 6.5% in the expression of only D 2 receptor (Matuskey et al., 2016) while D 3 receptors mantained a stable expression (Nakajima et al., 2015) . Although the association between age and D 2/3 receptor availability did not reach statistical significance, the age-related % decline of D 2/3 receptors was in line with the values previously reported, considering that PVEc might provide a slight difference in the estimation of agerelated changes of D 2/3 receptors. To the best of our knowledge PET studies with 11 C-raclopride using a high resolution PET system and PVEc are not available. In the present study, the decline rates for D 2/3 receptor availability in the striatum using the data without PVEc were in line with previously reported estimates (see Supplementary table 1) . The observed apparent increase of D 2/3 receptors with age in the globus pallidus was. mainly driven by one elderly subject with high BP ND values that was present also in the striatum. Without this subject the percent change of D 2/3 receptor availability in the globus pallidus was less than 2% per decade, suggesting rather stable levels of the D 2/3 receptors in this region. This finding was in agreement with the findings of a recent study (Nakajima et al., 2015) and could be partly explained by a different sub-regional vulnerability age-related process (Kim et al., 2011) .
Effect of age on Basal Ganglia Volume
The average volumetric measurements obtained for the striatum and the globus pallidus were consistent with normative datasets (Ifthikharuddin et al., 2000; Jovicich et al., 2009; Jovicich et al., 2013) . In the present study we observed a significant negative correlation between the volumes of striatum and age, even when adjusted for gender and ICV. The volume of the globus pallidus was rather stable with age. The pattern of age-related volume loss observed in the present study was in line with recent findings that described evident age-related structural brain changes even in subcortical structures such as a caudate and putamen and non relevant changes in the globus pallidus (Jiang et al., 2014; Lewis et al., 2016) . The negative linear correlation between morphometric measurements in the striatum and the age reinforces the hypothesis of a possible enhancement of partial volume effect (PVE) resulting in an underestimation of PDE10A and D 2/3 receptors availabilities. The application of a well-established partial volume effect method was thus important, despite the fact that such methods can be associated with possible biases due to noise amplification, and limitations related to the intrinsic presence of tissue in-homogeneities, susceptibility to suboptimal spatial realignments of the two modalities (PET and MR) and MR segmentation quality (Rousset et al., 2007) .
Gender related differences
Beside a strong age-related effects on PDE10A, as part of the analysis we observed an association of gender with the availability of both PDE10A enzyme and D 2/3 receptors (Table 3) . For both the molecular targets higher BP ND estimates were observed in the female group (see Fig. 1 ). Gender-related differences across the adult life span in the brain are well documented at different levels (volume of brain structures, brain chemistry and other receptor system) (Cosgrove et al., 2007; Ngun et al., 2011; de Vries and Södersten, 2009 ). The effects of gonadal hormones on striatal dopaminergic functions has also been detected preclinically (Becker, 1999) and gender differences in the phenotyphical expression of different striatal dopamine molecular targets in relation to neurodegenerative disease have been reported (Zielonka et al., 2013; Lee et al., 2015) .
With regards to gender-related effects, the present study presents some limitations. The distribution of female and male subjects that was not uniform across ages; only four female subjects were older than 50 years and most of the female subjects were in pre-menopausal age. Moreover, for female subjects information about possible different physiological hormonal levels (e.g. dates within mestrual cycles) were not available. Therefore, although the findings of the present study indicates that a gender effect on the availability or expression of PDE10A might be present, dedicated studies with a larger number of subjects across all ages are P. Fazio et al. NeuroImage 152 (2017) 330-339 required.
Distribution of PDE10A enzyme
The analysis of 18 F-MNI-659 data confirmed that the PDE10A enzyme is localized with high density in the striatum and in the globus pallidus. The regional distribution of 18 F-MNI-659 binding in the striatum in vivo observed in this study confirmed previous results obtained with the same radioligand Russell et al., 2016) . The availability of PDE10A enzyme in the globus pallidus was in the similar range as the PDE10A availability in the striatum (caudate and putamen). Although the availability of the PDE10A enzyme was examined in the whole globus pallidus segmented using FreeSurfer, with highresolution PET imaging it was possible to visualize the distribution of PDE10A enzyme in both internal and external globus pallidus ( Fig. 2A) . From the same representative image is also possible to visualize that negligible PDE10A availability are present in the nucleus accumbens (ventral striatum).
These findings are in agreement with immunohistochemistry (Coskran et al., 2006) and with ongoing autoradiographic studies (Svedberg et al., unpublished data) suggesting that the PDE10A enzyme is expressed in GABAergic medium spiny neurons both at the level of the cell bodies in the striatum and at the level of the terminals in the globus pallidus.
Despite the use of high-resolution PET and PVEc, the observed 18 F-MNI659 BP ND values both in the striatum and in the globus pallidus were highly variable between individuals ( Fig. 1 ) with a coefficient of variance (SD/mean *100 = COV%) equal to 27% in the striatum and to 36% in the globus pallidus. The variability observed is similar to the one described by Barret et al. for BP ND 18 F-MNI659 and might be to a certain extent related to the characteristics of the radioligand. Another possible explanation can be linked to a functional intrinsic molecular inter-individual variability of PDE10A, including variants of the gene that affect its regulation (McDonald et al., 2012) . The PDE10A enzyme is intracellular and can undergo different compartimentalization in the cytoplasma and Golgi complex (Kotera et al., 2004; Charych et al., 2010) or exists in different activation states (active or hyperactive) (Jäger et al., 2012) . Therefore, the binding of 18 F-MNI-659 might be influenced by differences in the intra-cellular environment or activation state of the enzyme across subjects, partly contributing to the observed inter-individual variability of the measured PDE10A availability.
Other groups have also showed that with a different radioligand PDE10A availability could additionally being explored and quantified in the substantia nigra (Niccolini et al., 2015b) . The binding of 18 F-MNI-659 in the substantia nigra was rather low, making the estimation of BP ND in this region quite challenging even after PVEc. In addition, this region cannot be segmented with standard 3T MRI sequences, making the estimation of PVEc sensitive to errors.
Distribution of D 2/3 receptors
The regional binding of 11 C-raclopride to D 2/3 receptors, as expected, was consistent with higher D 2/3 receptor availability in the striatum (putamen > caudate), followed by the nucleus accumbens and then by the external segment of the globus pallidus ( Fig. 2A) . The distribution of D 2/3 receptors was consistent with previous study using autoradiography on post-mortem brain tissue (Gurevich and Joyce, 1999; Glass et al., 2000; Sun et al., 2012) or with studies examining in vivo the distribution of D 2 receptors in the striatum with PET (Alakurtti et al., 2013; Mawlawi et al., 2001) . In the present study, the nucleus accumbens was not included in the data analysis because of very low specific binding of 18 F-MNI-659 observed using autoradiography on post-mortem brain tissue.
PVEc of 11 C-raclopride data resulted in a slight reduction of BP ND values in the globus pallidus (Supplementary figure 3) . The explanation for such correction is most likely related to the spill-over of radioactivity from putamen to globus pallidus. The globus pallidus is a region with a relative low density of D 2/3 receptors located mainly in the pars externa. Thus a fraction of measured binding in the globus pallidus without PVEc is most likely attributed to the binding in the putamen.
Relationship between D 2/3 Receptors and PDE10A enzyme In the present study, we found a statistical significant relationship of the distribution of D 2/3 receptors and PDE10A enzyme in the striatum. This relationship suggests a functional association between PDE10A and D 2/3 receptors under steady-state or resting conditions. Indeed, both molecular targets are mainly enriched in striatal medium spiny neurons and anatomically and functionally connected with the basal ganglia indirect pathway. In addition, dopamine's downstream effects are mediated through G protein-coupled receptors (GPCR) through cAMP, and PDE10A is implicated in the regulation of cAMP/cGMP related pathways (Grauer et al. 2009; Kotera et al., 2004) .
We did not find a statistical significant relationship of the distribution of D 2/3 receptors and PDE10A enzyme in the globus pallidus. A recent study has demonstrated that the D 2 -enriched striato-pallidal pathways can be activated after PDE10A inhibition . Therefore, although the two targets are not co-expressed in the globus pallidus, the functional activation of the D 2 -related pathway can probably still be mediated by PDE10A enzyme in this region.
Conclusion
The findings of this study suggest that aging is associated with a considerable physiological reduction of the availability of PDE10A enzyme in the striatum. PVEc is important to verify the extension and the contribution of volumetric changes to the availability of PDE10A enzyme and D 2/3 receptors. Appropriate age-matching is important for future clinical PET studies examining the difference of the availability of the PDE10A enzyme between control subjects and patients with neurodegenerative disorders, such as HD.
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